

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
7 February 2013 (07.02.2013)



(10) International Publication Number
WO 2013/019561 A8

(51) International Patent Classification:

C07D 213/50 (2006.01) *A61K 31/4196* (2006.01)
C07D 401/08 (2006.01) *A61K 31/454* (2006.01)
C07D 401/12 (2006.01) *A61K 31/4439* (2006.01)
C07D 401/14 (2006.01) *A61K 31/421* (2006.01)
C07D 403/08 (2006.01) *A61K 31/506* (2006.01)
C07D 403/12 (2006.01) *A61K 31/497* (2006.01)
C07D 413/12 (2006.01) *A61K 31/407* (2006.01)
C07D 487/10 (2006.01)

(21) International Application Number:

PCT/US2012/048368

(22) International Filing Date:

26 July 2012 (26.07.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/513,432	29 July 2011 (29.07.2011)	US
61/513,428	29 July 2011 (29.07.2011)	US
61/653,588	31 May 2012 (31.05.2012)	US

(71) Applicant (for all designated States except US): **KARY-OPHARM THERAPEUTICS, INC.** [US/US]; 2 Mercer Road, Natick, MA 01760 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SANDANAYAKA, Vincent, P.** [US/US]; 10 Laurel Avenue, Northboro, MA 01532 (US). **SHACHAM, Sharon** [IL/US]; 15 Bontempo Road, Newton, MA 02459 (US). **KAUFFMAN, Michael** [IL/US]; 15 Bontempo Road, Newton, MA 02459 (US). **SHECHTER, Sharon** [IL/US]; 18 Ivy Lane, Andover, MA 01810 (US). **MCCAULEY, Dilara** [US/US]; 85 Gore Street, Cambridge, MA 02141 (US). **LANDESMAN, Yosef** [US/US]; 260 Tappan Street, Brookline, MA 02445 (US). **SENAPEDIS, William** [US/US]; 364 Washington Street, Unit 6A, Brighton, MA 02135 (US). **SAINT-**

MARTIN, Jean-Richard [US/US]; 19 Decota Drive, Randolph, MA 02368 (US).

(74) Agents: **ABELLEIRA, Susan, M.** et al.; Hamilton, Brook, Smith & Reynolds, P.C., 530 Virginia Rd, P.O. Box 9133, Concord, MA 01742-9133 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))


(48) Date of publication of this corrected version:

4 July 2013

(15) Information about Correction:

see Notice of 4 July 2013

(54) Title: NUCLEAR TRANSPORT MODULATORS AND USES THEREOF



(57) Abstract: The invention generally relates to nuclear transport modulators, e.g. CRM1inhibitors, and more particularly to a compound represented by formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g. in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.



WO 2013/019561 A8